NPI-002 / Nacuity Pharma - LARVOL DELTA

NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Nacuity Pharmaceuticals, Inc. | Trial completion date: Feb 2025 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Oct 2025

Trial completion date • Trial primary completion date • Cataract • Ophthalmology

NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Nacuity Pharmaceuticals, Inc. | Trial completion date: Apr 2024 ➔ Feb 2025 | Trial primary completion date: Dec 2023 ➔ Oct 2024

Trial completion date • Trial primary completion date • Cataract • Ophthalmology

NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Nacuity Pharmaceuticals, Inc. | Trial completion date: Dec 2023 ➔ Apr 2024 | Trial primary completion date: Sep 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Cataract • Ophthalmology

NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Nacuity Pharmaceuticals, Inc. | Trial completion date: Feb 2023 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Sep 2023

Trial completion date • Trial primary completion date • Cataract • Ophthalmology

Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis. (PubMed, Orphanet J Rare Dis) - "NACA and diNACA were non cytotoxic to HCFs and significantly increased cell viability. Cystine reduction was determined as percent of control after incubation with 50 µM of NACA, diNACA or cysteamine in HCFs cell culture for 6, 24, 48 and 72 h. Of the three test articles, NACA exhibited most rapid and greatest potency in cystine reduction. Rank order potency for cystine reduction over time was observed, NACA > diNACA ≥ cysteamine. Therefore, further study of NACA and diNACA as potential treatments for cystinosis is warranted."

Journal • Preclinical • Gastrointestinal Disorder • Lysosomal Storage Diseases • Metabolic Disorders • Pain • Rare Diseases

NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Nacuity Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2022 ➔ Feb 2023 | Initiation date: Oct 2021 ➔ Jan 2022 | Trial primary completion date: Jul 2022 ➔ Dec 2022

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Cataract • Ophthalmology

NPI-002 Intravitreal Implant for the Delay of Cataract Progression (clinicaltrials.gov) - P1/2; N=30; Not yet recruiting; Sponsor: Nacuity Pharmaceuticals, Inc.

Clinical • New P1/2 trial • Cataract • Ophthalmology